The global extracorporeal membrane oxygenation machine market is expanding steadily, driven by the rising prevalence of cardiopulmonary and respiratory diseases, increasing adoption of ECMO machines in hospitals, technological advancements, and growing awareness of advanced life-support technologies. The market was valued at USD 307.9 million in 2023 and is estimated to reach USD 357.7 million in 2026. It is projected to reach USD 445.7 million by 2030, expanding at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2030. North America dominated the market with a 39.5% revenue share in 2023, while Asia Pacific is expected to register the fastest growth during the forecast period.

Download a free sample copy of the Extracorporeal Membrane Oxygenation Machine Market report to understand detailed coverage and inclusions in the final report 

Market Breakdown and Segmentation

• By Component: Oxygenators accounted for the largest revenue share of 34.61% in 2023 and are also expected to register the fastest CAGR during the forecast period. Increasing prevalence of chronic diseases, including chronic obstructive pulmonary disease (COPD), and growing demand for heart and lung transplantation procedures are supporting demand for oxygenators. Pumps also represent a significant component of ECMO machines because they move blood from the patient to the artificial lungs for oxygenation before returning it to the patient.

• By Modality: The veno-arterial (VA) segment accounted for the largest revenue share of 42.2% in 2023. VA ECMO is widely used for patients requiring both cardiac and respiratory support, including those experiencing cardiac arrest and severe cardiopulmonary failure. The veno-venous segment also held a significant market share and is expected to witness lucrative growth as it supports oxygen and carbon dioxide exchange in patients requiring lung support.

• By Application: Respiratory applications accounted for the largest revenue share of 44.10% in 2023 and are expected to register the fastest CAGR during the forecast period. The high prevalence of respiratory disorders and increasing demand for prolonged respiratory support are contributing to segment growth. Cardiac applications also represent an important area of use, supported by the increasing incidence of cardiac surgeries and growing awareness of ECMO technology.

• By Patient Type: The adult patient segment dominated the market with a 59.38% revenue share in 2023 and is expected to register the fastest CAGR through the forecast period. The segment's growth is supported by the increasing prevalence of coronary heart disease, respiratory disorders, and other conditions requiring advanced life-support technologies. Pediatric and neonatal applications also remain important areas for ECMO utilization.

Regional Dynamics

The ECMO machine market exhibits strong regional concentration, with North America leading the global industry and Asia Pacific representing an important growth market:

• North America: Dominated the global market with a 39.5% revenue share in 2023. The region benefits from sophisticated healthcare facilities, favorable reimbursement policies, high purchasing power, and the increasing prevalence of conditions such as COPD. The U.S. accounted for the largest share of the North American market in 2023, supported by well-developed healthcare infrastructure and a large patient population requiring ECMO machines.

• Europe: Represents an established ECMO market supported by developed healthcare systems, increasing prevalence of chronic cardiopulmonary diseases, and the availability of specialized critical-care infrastructure. Growing adoption of advanced life-support technologies is also contributing to regional demand.

• Asia Pacific: Expected to register the fastest growth during the forecast period. Rising healthcare expenditure by government and private organizations, economic development, improving healthcare infrastructure, and growing reimbursement initiatives across countries such as Japan, China, and India are supporting regional expansion. Japan accounted for the largest share of the Asia Pacific market in 2023.

• Latin America: Increasing healthcare investment and improving access to advanced critical-care technologies are creating opportunities for ECMO machine manufacturers. Brazil, Mexico, and Argentina are among the countries covered in the regional analysis.

• Middle East & Africa: Expanding healthcare infrastructure, rising demand for advanced medical technologies, and increasing investments in critical-care services are contributing to market development across the region.

Key Growth Drivers & Challenges

• Rising Cardiopulmonary Diseases: The increasing incidence of cardiovascular and respiratory conditions is creating greater demand for advanced life-support technologies. COPD and other severe respiratory disorders remain important factors supporting ECMO adoption. Grand View Research notes that COPD accounted for approximately 3.23 million deaths globally in 2019, highlighting the significant disease burden associated with respiratory conditions.

• Growing Hospital Adoption: Increasing adoption of ECMO machines in hospitals and the expansion of ECMO programs are supporting market growth. In the U.S., more than 100 new ECMO programs were established over the preceding three to five years, bringing the total number of ECMO programs to approximately 300 to 400.

• Technological Advancements: Manufacturers are developing ECMO systems with advanced oxygenators, hollow pumps, heparin-coated cannulas, and more compact designs. Portable adapters and compact ECMO circuits are also helping expand the use of ECMO systems in the transportation of critically ill patients.

• Growing Geriatric Population: An expanding elderly population and the increasing incidence of coronary heart disease are contributing to demand for advanced critical-care technologies. The growing burden of cardiovascular and respiratory diseases among older adults is supporting long-term adoption of ECMO systems.

• Market Challenges: Despite growth opportunities, ECMO adoption can be constrained by complications such as infections, bleeding, technical failures, and the high cost of treatment. The requirement for specialized healthcare professionals and sophisticated hospital infrastructure can also limit adoption in regions with constrained healthcare resources.

Looking for more specific insights? Customize this report to suite your business need

Key Market Players & Business Model Disruption

The ECMO machine market includes established medical device manufacturers and specialized companies competing through product development, acquisitions, partnerships, geographic expansion, and technological innovation. Key companies profiled by Grand View Research include:

• Medtronic Plc

• Maquet Holding

• Microport Scientific Corporation

• Terumo Cardiovascular System Corporation

• Medos Medizintechnik

• Nipro Medical Corporation

• LivaNova PLC

• CytoSorbents Corporation

• EUROSETS S.R.L

Innovation is increasingly focused on portable, miniaturized, and advanced ECMO systems. Companies are also pursuing strategic acquisitions and partnerships to expand product portfolios and strengthen their positions across emerging markets. For example, MicroPort Surgical acquired Hemovent in October 2021 to strengthen its emergency and critical-care capabilities and expand its ECMO technology portfolio. LivaNova received FDA 510(k) clearance for its LifeSPARC advanced circulatory support system in November 2022, while Inspira Technologies introduced its Liby System in July 2022 for patients with life-threatening heart and lung failure.